Q2 2026 13F · SEC CIK 2003147
Davern Capital Partners, LP
Institutional asset managerFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $586.5M
- Reported positions
- 15
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $715.1M
Davern Capital Partners, LP is an institutional asset manager that reported 15 positions worth $586.5M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Biontech SE (BNTX, 12.0%), Roivant Sciences Ltd (ROIV, 11.7%), Royalty Pharma PLC (RPRX, 11.0%).
Davern Capital Partners, LP holdings all 15 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| BNTXBiontech SE | 12.0% | +147.3% | $70.2M |
| ROIVRoivant Sciences Ltd | 11.7% | +121.3% | $68.4M |
| RPRXRoyalty Pharma PLC | 11.0% | +122.3% | $64.8M |
| IONSIonis Pharmaceuticals Inc | 10.8% | +106.4% | $63.3M |
| INSMInsmed Inc | 10.2% | +206.6% | $59.7M |
| REGNRegeneron Pharmaceuticals | 9.8% | +106.8% | $57.8M |
| LEGNLegend Biotech Corp | 5.9% | -9.4% | $34.4M |
| ALNYAlnylam Pharmaceuticals Inc | 5.8% | — | $34.0M |
| NTRANatera Inc | 5.5% | -17.4% | $32.3M |
| GPCRStructure Therapeutics F Unspo | 4.1% | +252.7% | $23.9M |
| MLYSMineralys Therapeutics Inc | 4.0% | +92.0% | $23.2M |
| VERAVera Therapeutics Inc Class A | 3.6% | — | $21.4M |
| GENBGenerate Biomedicines Inc | 2.4% | +39.4% | $13.9M |
| PRCTProcept Biorobotics Corp | 1.8% | +78.0% | $10.5M |
| AVTXAvalo Therapeutics Inc | 1.5% | — | $8.7M |
What Davern Capital Partners, LP bought and sold in Q2 2026, against Q1 2026.
New positions
- ALNY Alnylam Pharmaceuticals Inc5.8% of 13F
- VERA Vera Therapeutics Inc Class A3.6% of 13F
- AVTX Avalo Therapeutics Inc1.5% of 13F
Added to
- GPCR Structure Therapeutics F Unspo+252.7% shares
- INSM Insmed Inc+206.6% shares
- BNTX Biontech SE+147.3% shares
- RPRX Royalty Pharma PLC+122.3% shares
- ROIV Roivant Sciences Ltd+121.3% shares
- REGN Regeneron Pharmaceuticals+106.8% shares
- IONS Ionis Pharmaceuticals Inc+106.4% shares
- MLYS Mineralys Therapeutics Inc+92.0% shares
Reduced
- NTRA Natera Inc-17.4% shares
- LEGN Legend Biotech Corp-9.4% shares
Sold out
- PFE Pfizer Incwas 12.3%
- ARGNF Argenx SEwas 7.0%
- LLY Eli Lilly & Cowas 6.9%
- ABVX Abivax SAwas 2.4%
- VRDN Viridian Therapeutics Incwas 1.6%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $586.5M | 15 |
| Q1 2026 | $364.5M | 17 |
| Q4 2025 | $309.3M | 14 |
Questions about Davern Capital Partners, LP's portfolio
What stocks does Davern Capital Partners, LP own?
Davern Capital Partners, LP's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 15 positions worth $586.5M. The largest are Biontech SE (BNTX) at 12.0%, Roivant Sciences Ltd (ROIV) at 11.7%, Royalty Pharma PLC (RPRX) at 11.0%, Ionis Pharmaceuticals Inc (IONS) at 10.8% and Insmed Inc (INSM) at 10.2%.
What did Davern Capital Partners, LP buy last quarter?
In Q2 2026, Davern Capital Partners, LP added a new position in Alnylam Pharmaceuticals Inc (ALNY), a new position in Vera Therapeutics Inc Class A (VERA), a new position in Avalo Therapeutics Inc (AVTX), Structure Therapeutics F Unspo (GPCR) (+252.7% shares), Insmed Inc (INSM) (+206.6% shares) and Biontech SE (BNTX) (+147.3% shares), compared with its Q1 2026 filing.
What did Davern Capital Partners, LP sell last quarter?
In Q2 2026, Davern Capital Partners, LP sold all of Pfizer Inc (PFE), sold all of Argenx SE (ARGNF), sold all of Eli Lilly & Co (LLY), sold all of Abivax SA (ABVX), sold all of Viridian Therapeutics Inc (VRDN), Natera Inc (NTRA) (-17.4% shares) and Legend Biotech Corp (LEGN) (-9.4% shares), compared with its Q1 2026 filing.
When is Davern Capital Partners, LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Davern Capital Partners, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Davern Capital Partners, LP manage?
Davern Capital Partners, LP reported $715.1M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $586.5M.